Target Price | $65.56 |
Price | $12.50 |
Potential |
424.44%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Arcturus Therapeutics Ltd 2026 .
The average Arcturus Therapeutics Ltd target price is $65.56.
This is
424.44%
register free of charge
$140.00
1,020.00%
register free of charge
$41.00
228.00%
register free of charge
|
|
A rating was issued by 11 analysts: 11 Analysts recommend Arcturus Therapeutics Ltd to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Arcturus Therapeutics Ltd stock has an average upside potential 2026 of
424.44%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 138.39 | 96.43 |
12.27% | 30.32% | |
EBITDA Margin | -25.71% | -171.54% |
3,279.79% | 567.21% | |
Net Margin | -58.53% | -128.52% |
205.33% | 119.58% |
11 Analysts have issued a sales forecast Arcturus Therapeutics Ltd 2025 . The average Arcturus Therapeutics Ltd sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Arcturus Therapeutics Ltd EBITDA forecast 2025. The average Arcturus Therapeutics Ltd EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Arcturus Therapeutics Ltd Analysts have issued a net profit forecast 2025. The average Arcturus Therapeutics Ltd net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.00 | -4.59 |
167.86% | 53.00% | |
P/E | negative | |
EV/Sales | 0.78 |
3 Analysts have issued a Arcturus Therapeutics Ltd forecast for earnings per share. The average Arcturus Therapeutics Ltd EPS is
This results in the following potential growth metrics and future valuations:
Arcturus Therapeutics Ltd...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 10 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 10 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 07 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 07 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 18 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 14 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.